<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MITOTANE</span><br/>(mye'toe-tane)<br/><span class="topboxtradename">Lysodren<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Cytotoxic agent with suppressant action on the adrenal cortex. Modifies peripheral metabolism of steroids and reduces production
         of adrenal steroids. Extra-adrenal metabolism of cortisol is altered, leading to reduction in 17-hydroxycorticosteroids (17-OHCS);
         however, plasma levels of corticosteroids do not fall.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Cytotoxic agent with suppressant action on the adrenal cortex.</p>
<h1><a name="uses">Uses</a></h1>
<p>Inoperable adrenal cortical carcinoma (functional and nonfunctional).</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Cushing's syndrome secondary to pituitary disorders.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category C) or lactation (only after risk-benefit ratio to mother and fetus has been assessed).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adrenocortical Carcinoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 910 g/d in divided doses t.i.d. or q.i.d. (tolerated doses range: 216 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Withhold temporarily and consult physician if emergency occurs, since adrenal suppression is its prime action. Exogenous steroids
            may be required until the already depressed adrenal starts secreting steroids.
         </li>
<li>Store at 15°30° C (59°86° F) in tight, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Vertigo, dizziness, drowsiness, tiredness, depression, <span class="speceff-common">lethargy, sedation,</span> headache, confusion, tremors. <span class="typehead">CV:</span> Hypertension, hypotension, flushing. <span class="typehead">GI:</span> <span class="speceff-common">Anorexia, nausea, vomiting, diarrhea.</span> <span class="typehead">Urogenital:</span> Hematuria, hemorrhagic cystitis, albuminuria. <span class="typehead">Endocrine:</span> Adrenocortical insufficiency. <span class="typehead">Special Senses:</span> Blurred vision, diplopia, lens opacity, toxic retinopathy. <span class="typehead">Body as a Whole:</span> Generalized aching, fever, muscle twitching, hypersensitivity reactions, hyperpyrexia. <span class="typehead">Skin:</span> <span class="speceff-common">Rash,</span> cutaneous eruptions and pigmentation. <span class="typehead">Metabolic:</span> <span class="speceff-common">Hypouricemia, hypercholesterolemia.</span>
<h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Mitotane decreases <span class="alt">protein-bound iodine (PBI)</span> and <span class="alt">urinary 17-OHCS levels</span>.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Potentiates sedative effects of <b>alcohol</b> and other <span class="classification">cns depressants</span>; may increase the metabolism of <b>phenytoin,</b> <b>phenobarbital,</b> <b>warfarin,</b> decreasing their effectiveness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Approximately 40% absorbed from GI tract. <span class="typehead">Onset:</span> 24 wk. <span class="typehead">Peak:</span> 35 h. <span class="typehead">Distribution:</span> Deposits in most body tissues, especially adipose tissue. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Small amount excreted in bile. <span class="typehead">Half-Life:</span> 18159 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor pulse and BP for early signs of shock (adrenal insufficiency).</li>
<li>Observe for symptoms of hepatotoxicity (see Appendix F). Report them promptly, since reduced hepatic capacity can increase
            toxicity of mitotane and because dose may have to be decreased.
         </li>
<li>Notify physician if following persist and become more severe: Aching muscles, fever, flushing, and muscle twitching.</li>
<li>Monitor obese patient for symptoms of adrenal hypofunction. Because a large portion of the drug deposits in fatty tissue,
            the obese are particularly susceptible to prolonged adverse effects.
         </li>
<li>Make neurologic and behavioral assessments at regular intervals throughout therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that mitotane does not cure but does reduce tumor mass, pain, weakness, anorexia, and steroid symptoms.</li>
<li>Report symptoms of adrenal insufficiency (weakness, fatigue, orthostatic hypotension, pigmentation, weight loss, dehydration,
            anorexia, nausea, vomiting, and diarrhea) to physician.
         </li>
<li>Exercise caution when driving or performing potentially hazardous tasks requiring alertness because of drug-induced drowsiness,
            tiredness, dizziness. Symptoms tend to recede with continuation in therapy.
         </li>
<li>Use contraceptive measures during therapy because of teratogenic properties of drug. Notify physician if you suspect you are
            pregnant.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>